OPB-111077 + bendamustine + rituximab

OPB-111077 + bendamustine + rituximab is an investigational **three-drug combination** therapy primarily evaluated for the treatment of hematologic malignancies. **OPB-111077** is a novel, orally available, small-molecule inhibitor targeting **signal transducer and activator of transcription 3 (STAT3)** and **mitochondrial oxidative phosphorylation (OXPHOS)**[1][3][5]. This inhibition can induce tumor cell apoptosis and impair metabolic functions required for cancer cell survival. **Bendamustine** is an alkylating agent, structurally unique for its benzimidazole ring, with activity in lymphoid malignancies and known to circumvent cross-resistance to older alkylators[2][4]. **Rituximab** is a monoclonal antibody that targets the **CD20** antigen on B lymphocytes, leading to cell death through immune-mediated and direct mechanisms[2][4]. Preclinical and early-phase clinical data support the use of OPB-111077 in combination with standard chemotherapies to overcome resistance mechanisms, particularly in lymphoid cancers such as diffuse large B-cell lymphoma (DLBCL).[1][2][3][5] The standard BR regimen (bendamustine + rituximab) shows modest efficacy and a tolerable safety profile in DLBCL and indolent non-Hodgkin lymphoma, with OPB-111077 investigated as an add-on for enhanced therapeutic response and targeting of chemotherapy-resistant cell populations.